Table 2.
Improvement of lung function after treatment in each group.
| rs20541 genotype | Cases (n) | FEV1 (%) before treatment* | FEV1 (%) after treatment | P | PEF (%) before treatment** | PEF (%) after treatment | P |
|---|---|---|---|---|---|---|---|
| GG | 22 | 89.41 ± 1.71 | 96.55 ± 1.14 | 0.000 | 89.41 ± 1.71 | 96.73 ± 1.08 | 0.000 |
| GA | 17 | 88.24 ± 1.35 | 91.47 ± 2.03 | 0.000 | 88.24 ± 1.35 | 92.18 ± 1.81 | 0.000 |
| AA | 11 | 88.45 ± 1.57 | 91.91 ± 1.45 | 0.000 | 88.45 ± 1.57 | 91.73 ± 1.27 | 0.04 |
*: Before treatment, FEV1 (%) did not significantly differ among the three groups (P = 0.57).
**: Before treatment, PEF (%) did not significantly differ among the three groups (P = 0.22).
FEV1, forced expiratory volume in 1 s; PEF, percent predicted peak expiratory flow.